A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is application/pdf
.
Levofloxacin prophylaxis for pediatric leukemia patients: Longitudinal follow‐up for impact on health care‐associated infections
2022
Pediatric Blood & Cancer
Bloodstream infections (BSIs) cause morbidity and mortality in pediatric patients with leukemia. Antibiotic prophylaxis during periods of chemotherapy-induced neutropenia may reduce the incidence of BSIs. A levofloxacin prophylaxis guideline was implemented for pediatric patients with acute myeloid leukemia and relapsed acute lymphoblastic leukemia. We conducted a retrospective cohort study over 4 years (2 years pre and 2 years post implementation) of the practice guideline to assess the impact
doi:10.1002/pbc.29525
pmid:35029328
fatcat:3zzg22lfu5c77c7x5jnghmaeam